Relief Therapeutics Holding AG (RLF.SW)
CHF 4.1
(-6.82%)
CHF 4.1
(-6.82%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -8.35 CHF | -73.96% |
| 2022 | -4.80 CHF | -24.35% |
| 2021 | -3.86 CHF | -196.92% |
| 2020 | -1.30 CHF | 8.45% |
| 2019 | -1.42 CHF | -1568.63% |
| 2018 | -0.09 CHF | 85.33% |
| 2017 | -0.58 CHF | 89.1% |
| 2016 | -5.32 CHF | 14.74% |
| 2015 | -6.24 CHF | 39.65% |
| 2014 | -10.34 CHF | 63.6% |
| 2013 | -28.41 CHF | 23.63% |
| 2012 | -37.20 CHF | 89.17% |
| 2011 | -343.40 CHF | -194.33% |
| 2010 | -116.67 CHF | -1193.46% |
| 2009 | -9.02 CHF | -25.1% |
| 2008 | -7.21 CHF | 6.0% |
| 2007 | -7.67 CHF | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -0.36 CHF | 0.0% |
| 2023 Q2 | -5.10 CHF | 0.0% |
| 2023 FY | - CHF | -73.96% |
| 2023 Q4 | -3.32 CHF | 0.0% |
| 2022 FY | - CHF | -24.35% |
| 2022 Q2 | -2.55 CHF | 0.0% |
| 2022 Q4 | -2.25 CHF | 0.0% |
| 2021 Q2 | -1.76 CHF | 0.0% |
| 2021 Q4 | -2.10 CHF | 0.0% |
| 2021 FY | - CHF | -196.92% |
| 2020 Q2 | 1.54 CHF | 0.0% |
| 2020 FY | - CHF | 8.45% |
| 2020 Q4 | -2.83 CHF | 0.0% |
| 2019 Q2 | -0.11 CHF | 0.0% |
| 2019 FY | - CHF | -1568.63% |
| 2019 Q4 | -1.31 CHF | 0.0% |
| 2018 Q2 | -0.07 CHF | 0.0% |
| 2018 Q4 | -0.01 CHF | 0.0% |
| 2018 FY | - CHF | 85.33% |
| 2017 FY | - CHF | 89.1% |
| 2017 Q4 | -0.37 CHF | 0.0% |
| 2017 Q2 | -0.21 CHF | 0.0% |
| 2016 Q1 | -0.00 CHF | 0.0% |
| 2016 FY | - CHF | 14.74% |
| 2016 Q2 | -0.17 CHF | -5051.52% |
| 2016 Q4 | -3.51 CHF | 0.0% |
| 2015 Q3 | -0.00 CHF | 0.0% |
| 2015 FY | - CHF | 39.65% |
| 2015 Q1 | -0.00 CHF | 0.0% |
| 2015 Q4 | -0.00 CHF | -106.25% |
| 2015 Q2 | -0.00 CHF | 0.0% |
| 2014 Q4 | -0.00 CHF | 75.38% |
| 2014 FY | - CHF | 63.6% |
| 2014 Q3 | -0.01 CHF | 0.0% |
| 2014 Q2 | -0.01 CHF | 0.0% |
| 2014 Q1 | -0.01 CHF | 0.0% |
| 2013 Q4 | -0.01 CHF | 63.48% |
| 2013 Q3 | -0.02 CHF | 0.0% |
| 2013 Q2 | -0.02 CHF | 0.0% |
| 2013 Q1 | -0.02 CHF | 0.0% |
| 2013 FY | - CHF | 23.63% |
| 2012 FY | - CHF | 89.17% |
| 2012 Q4 | -0.02 CHF | 23.93% |
| 2012 Q2 | -0.02 CHF | 0.0% |
| 2012 Q1 | -0.02 CHF | 0.0% |
| 2012 Q3 | -0.02 CHF | 0.0% |
| 2011 Q2 | -0.22 CHF | 0.0% |
| 2011 Q4 | -0.02 CHF | 89.36% |
| 2011 FY | - CHF | -194.33% |
| 2011 Q3 | -0.22 CHF | 0.0% |
| 2011 Q1 | -0.22 CHF | 0.0% |
| 2010 Q1 | -0.01 CHF | 0.0% |
| 2010 Q4 | -0.22 CHF | -2317.58% |
| 2010 Q3 | -0.01 CHF | 0.0% |
| 2010 Q2 | -0.01 CHF | 0.0% |
| 2010 FY | - CHF | -1193.46% |
| 2009 Q2 | -0.01 CHF | 0.0% |
| 2009 Q3 | -0.01 CHF | 0.0% |
| 2009 Q4 | -0.01 CHF | -62.5% |
| 2009 FY | - CHF | -25.1% |
| 2009 Q1 | -0.01 CHF | 0.0% |
| 2008 Q4 | -0.01 CHF | 71.57% |
| 2008 Q2 | -0.02 CHF | 0.0% |
| 2008 Q1 | -0.02 CHF | 0.0% |
| 2008 FY | - CHF | 6.0% |
| 2008 Q3 | -0.02 CHF | 0.0% |
| 2007 FY | - CHF | 0.0% |
| 2007 Q3 | -0.00 CHF | 0.0% |
| 2007 Q2 | -0.00 CHF | 0.0% |
| 2007 Q1 | -0.00 CHF | 0.0% |
| 2007 Q4 | -0.02 CHF | -310.42% |
| 2006 Q4 | -0.00 CHF | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Addex Therapeutics Ltd | -0.14 CHF | -5864.286% |
| BB Biotech AG | -3.77 CHF | -121.485% |
| Basilea Pharmaceutica AG | 0.87 CHF | 1059.77% |
| Evolva Holding SA | -19.50 CHF | 57.179% |
| Idorsia Ltd | -1.67 CHF | -400.0% |
| Kuros Biosciences AG | -0.38 CHF | -2097.368% |
| Molecular Partners AG | -1.89 CHF | -341.799% |
| Santhera Pharmaceuticals Holding AG | 5.18 CHF | 261.197% |